IMS Health Economics and Outcomes Research has considerable expertise and database knowledge gained from experience in the US, European and Asia Pacific markets that can be used to help you to assess current market status and growth potential, as well as identify new opportunities. At the heart of IMS's research capabilities in this area are the IMS Disease Analyzer, the PharMetrics Profiler series and SKI database. In addition to these we have data expertise via IMS Oncology Analyzer and Acute cardiovascular databases.
Disease Analyzer is a unique longitudinal patient database sourced from primary care physicians that tracks patients and their resource use across a variety of treatment pathways in four European countries (Austria, France, Germany and the UK) combining 15.7 million individual patient records with some patients followed for 14 years.
IMS Oncology Analyzer is a diary-derived database of comprehensive patient case history information, based on advanced reporting from hospital clinicians. It provides a full therapeutic itinerary by patient from present day back to diagnosis enabling all aspects of the cancer treatment process to be analysed:
-
Full treatment history - surgery, radiotherapy, chemotherapy, supportive care
-
Patient segmentation - by indication, stage and line of therapy
-
Patient pathways and initiation of prescribing
-
Prescriber, patient & product profiling
-
Treatment practice patterns
-
Product uptake and penetration
Similar information is available for patients with Acute Cardiovascular Diseases and Stroke treated in hospitals.
PharMetrics uses the largest available data source of integrated medical and pharmaceutical claims in the USA, to provide marketers with a complete picture of patient treatment across the continuum of care. With more than 55 million unique individuals represented by more than 85 health plans, this databank started in 1995 is truly representative of the US population.
SKI ReferencePoint is a longitudinal employer based database with 45M million patients over 5 years with an average of an average of 9.1M patients per year (low turnover). ReferencePoint includes a spectrum of age groups, and are geographically represented compared to US Census tract information. Since coverage for older Americans is offered, representation of patients aged 65+ is robust as are children under 17 years of age. Data include detailed information surrounding:
-
Retail prescriptions
-
Encounter base medical care
-
Facility type (outpatient clinic, Long Term Care, hospital etc)
-
Laboratory, radiology and pathology results; as well as limited occupational information.
ReferencePoint has unique characteristics which allow for provider and pharmacy identifiably, the ability to break down ages of children by month, and visibility into nursing home pharmaceutical administration and procedures.
These rich data sources provide, combined with IMS medical and hospital data and information on product pricing in the majority of countries worldwide, a full and realistic picture of:
-
Hospital and referral rates
-
Cost of medicines (first-line, second-line, to treat adverse events)
-
Other interventions
-
Outcomes of treatment (reduction in blood pressure, etc)
-
Co-morbidities
-
Treatment persistence and compliance